| __timestamp | Apellis Pharmaceuticals, Inc. | Genmab A/S |
|---|---|---|
| Wednesday, January 1, 2014 | 8379522 | 505679000 |
| Thursday, January 1, 2015 | 13730311 | 487656000 |
| Friday, January 1, 2016 | 22978599 | 660876000 |
| Sunday, January 1, 2017 | 40303878 | 874278000 |
| Monday, January 1, 2018 | 105285576 | 1431159000 |
| Tuesday, January 1, 2019 | 220968770 | 2386000000 |
| Wednesday, January 1, 2020 | 299921000 | 3137000000 |
| Friday, January 1, 2021 | 420869000 | 4181000000 |
| Saturday, January 1, 2022 | 387236000 | 5562000000 |
| Sunday, January 1, 2023 | 354387000 | 7630000000 |
| Monday, January 1, 2024 | 9748000000 |
In pursuit of knowledge
In the ever-evolving landscape of biotechnology, research and development (R&D) investments are pivotal. Over the past decade, Genmab A/S and Apellis Pharmaceuticals, Inc. have demonstrated contrasting trajectories in their R&D expenditures. Genmab A/S, a leader in antibody therapeutics, has consistently outpaced Apellis, with its R&D spending surging by over 1,400% from 2014 to 2023. In 2023 alone, Genmab's investment reached a staggering 7.63 billion, reflecting its commitment to innovation.
Conversely, Apellis Pharmaceuticals, known for its focus on complement system therapies, has shown a more modest growth of approximately 4,100% in the same period. Despite this, Apellis's R&D spending peaked in 2021, highlighting a strategic shift. This comparison underscores the diverse strategies within the biotech sector, where both companies continue to push the boundaries of medical science.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Genmab A/S
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Genmab A/S
R&D Insights: How GSK plc and Apellis Pharmaceuticals, Inc. Allocate Funds
Biogen Inc. or Genmab A/S: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Genmab A/S and Insmed Incorporated
Research and Development Expenses Breakdown: Genmab A/S vs Lantheus Holdings, Inc.
Analyzing R&D Budgets: Genmab A/S vs MorphoSys AG
Research and Development Expenses Breakdown: Genmab A/S vs Vericel Corporation
R&D Spending Showdown: Genmab A/S vs Ligand Pharmaceuticals Incorporated
Research and Development: Comparing Key Metrics for Genmab A/S and Wave Life Sciences Ltd.
Research and Development: Comparing Key Metrics for Apellis Pharmaceuticals, Inc. and Bausch Health Companies Inc.
Research and Development: Comparing Key Metrics for Apellis Pharmaceuticals, Inc. and Evotec SE